A Phase 2 interventional study of KD025 in Psoriasis Vulgaris, sponsored by Kadmon Corporation, LLC. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-26.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 437th largest by enrollment of the 673 interventional ones that give a count, is one of 39 that started in 2014, is one of 200 in phase 2, and was the 333rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 39 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon Corporation, LLC, one of the names counted as Sanofi. Under that name alone:
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Sanofi has 5 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one line of systemic therapy.
Study KD025-206 was a phase 2, open-label, dose-finding, safety, tolerability, activity, and PK study of KD025 in subjects with psoriasis who had failed at least 1 line of systemic therapy or phototherapy.
Subjects received KD025 PO for 12 weeks. Planned enrollment was 36 subjects in 3 cohorts, 12 subjects per cohort:
Subjects were initially enrolled simultaneously in Cohort 1 and Cohort 2 according to a randomization schedule, with safety reviewed before any subjects. If safety guidelines were met, Cohort 3 was added to explore the efficacy and safety of KD025 at a dose of 400 mg PO BID.
Subjects underwent safety evaluations: medical history evaluations; physical examinations (PEs); vital sign measurements; weight measurements; adverse event (AE) assessments; concomitant medication assessments; blood sample collection for hematology, chemistry, and coagulation; lipid panel; thyroid-stimulating hormone; measurements of antinuclear antibody; anti-double-stranded deoxyribonucleic acid; Complement C; antiphospholipid antibody; liver ultrasound (US); pregnancy testing for females of childbearing potential; PK sampling (subset of subjects only); urinalysis; and electrocardiogram (ECG).
Subjects underwent efficacy evaluations: Psoriasis Area and Severity Index (PASI) scoring; Physicians Global Assessment (PGA) scoring; and Dermatologic Life Quality Index (DLQI) scoring.
Subjects participating in PK sampling were admitted to the clinic on Month 1 Day 1 (M1D1) for PK procedures and were discharged on M2D2. Blood samples for PK analyses were collected on M2D1 and Month 3 Day 1 (M3D1) on an outpatient basis. Subjects were not to take their morning dose until after blood samples were drawn.
A Follow-Up visit occurred 30 ± 3 days after the last dose of study drug.
The endpoints for efficacy were PASI, PGA, and DSQI scores.
Safety was assessed by standard clinical and laboratory tests (hematology, serum chemistry, and urinalysis), PEs, and reporting of treatment-emergent adverse events (TEAEs). Toxicity grades were defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In addition, subjects had liver ultrasound and liver functioning testing assessed for possible steatosis.
Blood samples for determination of PK plasma concentrations of KD025 and its metabolites were collected for maximum concentration (Cmax); time of maximum concentration (Tmax); area under the concentration-time curve (AUC) at 0 to 24 hours, 0 to last, and 0 to infinity (0 to 24, 0 to last, 0 to infinity [inf]); half-life (t1/2); and accumulation ratio (metabolic-to-parent drug ratio).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KD025 400 mg QD PO for 12 weeks
Drug: KD025
KD025 200 mg BID PO for 12 weeks
Drug: KD025
KD025 400 mg BID PO for 12 weeks
Drug: KD025
Also known as: SLx-2119, belumosudil
Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population
Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 12 weeks
Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population
Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 12 weeks
Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population
Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.
Time frame: 12 weeks
Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population
Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
Time frame: 12 weeks
Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population
Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
Time frame: 12 weeks
Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 4 weeks
Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 8 weeks
Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 12 weeks
Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
Time frame: 12 weeks
Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population
Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
Time frame: 4 weeks
Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population
Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
Time frame: 8 weeks
Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population
Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
Time frame: 8 weeks
Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement
Time frame: 4 weeks
Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement
Time frame: 8 weeks
Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement
Time frame: 12 weeks
Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.
Time frame: 12 weeks
Efficacy: Mean Changes in DLQI at EOT--ITT Population
Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable
Time frame: 12 weeks
Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population
Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable.
Time frame: 12 weeks
Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2
Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)
Time frame: 24 hours
Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2
Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2): AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time "t" post-dose
Time frame: 24 hours
Pharmacokinetics: t(1/2) of KD025
Half-life (t\[1/2\]) of Parent drug (KD025)
Time frame: 24 hours
Pharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2
Metabolite-to-parent ratio of maximum concentration (MR C\[max\]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time "t" for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)
Time frame: 24 hours
| Milestone | 400 mg QD | 200 mg BID | 400 mg BID |
|---|---|---|---|
| Started | 13 | 13 | 12 |
| Completed | 11 | 8 | 8 |
| Not completed | 2 | 5 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Stopped by investigator | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 | 3 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| ≥ 75% Reduction from Baseline | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 9.1 (0.2 to 41.3) | 11.4 (3.2 to 26.7) |
| ≥ 50% Reduction from Baseline | 41.7 (15.2 to 72.3) | 50.0 (21.1 to 78.9) | 18.2 (2.3 to 51.8) | 37.1 (21.5 to 55.1) |
Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| ≥ 75% Reduction from Baseline | 16.7 (2.1 to 48.4) | 14.3 (0.4 to 57.9) | 14.3 (0.4 to 57.9) | 15.4 (4.4 to 34.9) |
| ≥ 50% Reduction from Baseline | 41.7 (15.2 to 72.3) | 71.4 (29.0 to 96.3) | 28.6 (3.7 to 71.0) | 46.2 (26.6 to 66.6) |
Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| All AEs | 12 | 11 | 8 | 31 |
| Grade 1 (Mild) | 69.2 | 46.2 | 33.3 | 50.0 |
| Grade 2 (Moderate) | 69.2 | 46.2 | 50.0 | 55.3 |
| Grade 3 (Severe) | 7.7 | 7.7 | 8.3 | 7.9 |
| Grade 4 (Life-threatening) | 7.7 | 0 | 0 | 2.6 |
| Grade 5 (Death) | 0 | 0 | 0 | 0 |
| Related to KD025 | 38.5 | 23.1 | 58.3 | 39.5 |
| Grade 3, 4, or 5 Related to KD025 | 0 | 7.7 | 0 | 2.6 |
Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| End of Treatment (or 12 Weeks) | 12.4 (7.9 to 17.0) | 10.3 (7.0 to 13.6) | 14.4 (8.8 to 19.9) | 12.3 (9.9 to 14.7) |
| Change from Baseline at End of Treatment | -8.8 (-16.5 to -1.1) | -6.0 (-9.5 to -2.4) | -4.8 (-8.9 to -0.7) | -6.6 (-9.5 to -3.7) |
Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| 12 Weeks | 12.4 (7.9 to 17.0) | 7.6 (5.6 to 9.6) | 15.5 (5.8 to 25.1) | 12.0 (8.9 to 15.0) |
| Change from Baseline at 12 Weeks | -8.8 (-16.5 to -1.1) | -7.9 (-11.9 to -3.9) | -5.9 (-12.5 to 0.7) | -7.8 (-11.4 to -4.1) |
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population | 76.9 (46.2 to 95.0) | 66.7 (34.9 to 90.1) | 58.3 (27.7 to 84.8) | 67.6 (50.2 to 82.0) |
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population | 83.3 (51.6 to 97.9) | 100 (66.4 to 100) | 85.7 (42.1 to 99.6) | 89.3 (71.8 to 97.7) |
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population | 75.0 (42.8 to 94.5) | 75.0 (42.8 to 94.5) | 81.8 (48.2 to 97.7) | 77.1 (59.9 to 89.6) |
The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]
| Percentage of participants (%) | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| 4 Weeks | 75.0 (42.8 to 94.5) | 85.7 (42.1 to 99.6) | 71.4 (29.0 to 96.3) | 76.9 (56.4 to 91.0) |
| 8 Weeks | 83.3 (51.6 to 97.9) | 100 (59.0 to 100) | 85.7 (42.1 to 99.6) | 88.5 (69.8 to 97.6) |
| 12 Weeks | 75.0 (42.8 to 94.5) | 100 (59.0 to 100) | 85.7 (42.1 to 99.6) | 84.6 (65.1 to 95.6) |
Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population | -4.7 (-7.8 to -1.6) | -2.6 (-5.3 to 0) | -2.3 (-5.5 to 1.0) | -3.2 (-4.8 to -1.6) |
Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population | -8.6 (-15.0 to -2.1) | -6.4 (-9.6 to -3.2) | -4.7 (-10.0 to 0.6) | -6.9 (-9.8 to -4.0) |
Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| 4 Weeks | -4.4 (-7.8 to -1.1) | -3.5 (-7.2 to 0.2) | -2.7 (-8.1 to 2.7) | -3.7 (-5.7 to -1.7) |
| 8 Weeks | -8.6 (-15.0 to -2.1) | -6.8 (-10.9 to -2.7) | -4.7 (-10.0 to 0.6) | -7.1 (-10.2 to -3.9) |
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement
| Percentage of participants | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Clear/Excellent (75% to 100% Improvement) | 0 | 0 | 0 | 0 |
| Good (50% to 74% Improvement) | 7.7 | 8.3 | 8.3 | 8.1 |
| Fair (25% to 49% Improvement) | 46.2 | 58.3 | 41.7 | 48.6 |
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement
| Percentage of participants | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Clear/Excellent (75% to 100% Improvement) | 8.3 | 0 | 0 | 3.6 |
| Good (50% to 74% Improvement) | 25.0 | 11.1 | 14.3 | 17.9 |
| Fair (25% to 49% Improvement) | 25.0 | 88.9 | 42.9 | 50.0 |
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement
| Percentage of participants | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Clear/Excellent (75% to 100% Improvement) | 0 | 0 | 0 | 0 |
| Good (50% to 74% Improvement) | 33.3 | 25.0 | 18.2 | 25.7 |
| Fair (25% to 49% Improvement) | 33.3 | 50.0 | 36.4 | 40.0 |
Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.
| Percentage of participants | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| 4 Weeks: Clear/Excellent | 0 | 0 | 0 | 0 |
| 4 Weeks: Good | 8.3 | 0 | 14.3 | 7.7 |
| 4 Weeks: Fair | 41.7 | 85.7 | 42.9 | 53.8 |
| 8 Weeks: Clear/Excellent | 8.3 | 0 | 0 | 3.8 |
| 8 Weeks: Good | 25.0 | 0 | 14.3 | 15.4 |
| 8 Weeks: Fair | 25.0 | 100 | 42.9 | 50.0 |
| 12 Weeks: Clear/Excellent | 0 | 0 | 0 | 0 |
| 12 Weeks: Good | 33.3 | 14.3 | 28.6 | 26.9 |
| 12 Weeks: Fair | 33.3 | 85.7 | 28.6 | 46.2 |
Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Mean Changes in DLQI at EOT--ITT Population | -4.9 ± 4.68 | -5.1 ± 5.35 | -2.5 ± 4.50 | -4.2 ± 4.86 |
Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable.
| Score on a scale | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population | -4.9 ± 4.68 | -6.3 ± 5.82 | -2.3 ± 2.93 | -4.6 ± 4.71 |
Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)
| ng/mL | 400 mg QD | 200 mg BID |
|---|---|---|
| KD025 | 3140 ± 1760 | 1770 ± 1190 |
| KD025m1 | 23.2 ± 9.66 | 22.8 ± 15.3 |
| KD025m2 | 632 ± 278 | 203 ± 204 |
Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2): AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time "t" post-dose
| hour*ng/mL | 400 mg QD | 200 mg BID |
|---|---|---|
| KD025: AUC(0-12) | 16200 ± 8910 | 9150 ± 5950 |
| KD025m2: AUC(0-12) | 2300 ± 907 | 757 ± 823 |
| KD025: AUC(0-24) | 18800 ± 10600 | 21800 ± 13900 |
| KD025m2: AUC(0-24) | 2510 ± 1180 | 1790 ± 1850 |
| KD025: AUC(0-t) | 18800 ± 10600 | 25100 ± 14800 |
| KD025m1: AUC(0-t) | 93.4 ± 18.1 | 250 ± 0 |
| KD025m2: AUC(0-t) | 2550 ± 1080 | 1960 ± 1950 |
Half-life (t\[1/2\]) of Parent drug (KD025)
| Hours | 400 mg QD | 200 mg BID |
|---|---|---|
| Pharmacokinetics: t(1/2) of KD025 | 8.00 ± 2.47 | 5.13 ± 1.12 |
Metabolite-to-parent ratio of maximum concentration (MR C\[max\]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time "t" for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)
| Number (ratio) | 400 mg QD | 200 mg BID |
|---|---|---|
| KD025m1: MR C(max) | 0.00736 ± 0.00272 | 0.00984 ± 0.00287 |
| KD025m2: MR C(max) | 0.199 ± 0.0794 | 0.101 ± 0.0469 |
| KD025m1: MR AUC(0-t) | 0.00458 ± 0.00253 | 0.00577 ± 0 |
| KD025m2: MR AUC(0-t) | 0.133 ± 0.0449 | 0.0719 ± 0.0336 |
Collected over Screening Period ≤ 4 week Screening Period + 12-week Treatment Period + 30-day Follow-up = Up to 20 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 mg QD | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| 200 mg BID | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| 400 mg BID | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Overall (All Subjects) | 0/38 (0%) | 0/38 (0%) | 31/38 (81.6%) |
| Event | 400 mg QD | 200 mg BID | 400 mg BID | Overall (All Subjects) |
|---|---|---|---|---|
| Alanine aminotransaminase (ALT) increasedInvestigations | 1/13 | 0/13 | 4/12 | 5/38 |
| Aspartate aminotransferase (AST) increasedInvestigations | 1/13 | 0/13 | 2/12 | 3/38 |
| Upper respiratory tract infectionInfections and infestations | 0/13 | 0/13 | 2/12 | 2/38 |
| DiarrheaGastrointestinal disorders | 2/13 | 0/13 | 1/12 | 3/38 |
| NauseaGastrointestinal disorders | 0/13 | 2/13 | 1/12 | 3/38 |
| VomitingGastrointestinal disorders | 1/13 | 2/13 | 0/12 | 3/38 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/13 | 2/13 | 0/12 | 2/38 |
| Liver function test abnormalInvestigations | 1/13 | 1/13 | 1/12 | 3/38 |
| Back painMusculoskeletal and connective tissue disorders | 1/13 | 0/13 | 1/12 | 2/38 |
| PruritusSkin and subcutaneous tissue disorders | 1/13 | 0/13 | 1/12 | 2/38 |
Intent-to-Treat (ITT) defined as all subjects enrolled in the study
| Age, Continuous(years) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Mean | 44.6 ± 10.32 | 46.5 ± 11.92 | 50.5 ± 10.26 | 47.1 ± 10.86 |
| Age, Continuous(years) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Median | 46.0 (29 to 60) | 45.0 (25 to 67) | 54.5 (30 to 64) | 47.5 (25 to 67) |
| Sex: Female, Male(Participants) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Female | 5 | 6 | 4 | 15 |
| Male | 8 | 7 | 8 | 23 |
| Ethnicity (NIH/OMB)(Participants) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 6 | 15 |
| Not Hispanic or Latino | 8 | 9 | 6 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 11 | 12 | 12 | 35 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| BMI (body mass index)--Mean(kg/m^2) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Mean | 34.42 ± 7.132 | 32.81 ± 7.747 | 32.65 ± 10.582 | 33.31 ± 8.362 |
| BMI--Median(kg/m^2) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Median | 35.70 (22.2 to 45.4) | 31.40 (23.4 to 51.4) | 30.35 (22.7 to 63.8) | 31.50 (22.2 to 63.8) |
| Psoriasis Area and Severity Index (PASI) Score--Mean(Units on a scale) | 400 mg QD | 200 mg BID | 400 mg BID | Total |
|---|---|---|---|---|
| Mean | 21.0 ± 10.85 | 18.3 ± 8.51 | 20.3 ± 7.24 | 19.8 ± 8.87 |
4 further baseline measures are reported on the registry.
The record gives a start of Dec 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2021, 5 years 8 months after primary completion. A results delay was requested in Apr 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil